Categories: world

Imperial launches the world's first center for psychedelic research | Imperial News

The first formal center for psychedelic research in the world will be launched at Imperial College London today. Funded with more than £ 3 million from five founding donors, the new Imperial Center for Psychedelic Research will build on over a decade of groundbreaking work in this field conducted at Imperial, including a clinical trial that has launched global efforts for to develop psilocybin treatment for a licensed treatment for depression. It will also examine their potential for treating other conditions, including anorexia. Led by Dr. Robin Carhart-Harris, the center will focus on two main research topics: the use of psychedelics in mental care; and as a tool to investigate the brain's consciousness basis. Psychedelic therapy is very much allowed to treat some very serious mental illnesses and can one day offer new hope to vulnerable people with limited treatment options Dr. Robin Carhart-Harris Head of Center for Psychedelic Research, Imperial College London The newly established center will be based on Imperial's Hammersmith campus, which shares space between Imperial College London and the Imperial College Healthcare NHS Trust. The center also aims to develop a research clinic that can contribute to gathering further clinical evidence and become a prototype for future licensed psychedelic care facilities. Dr Robin Carhart-Harris, Head of the Imperial Center for Psychedelic Research, said: "This new center represents a watershed for psychedelic science, symbolic of its current general recognition. Psychiatric has a significant impact on neuroscience and psychiatry in the near future. It is a privilege to…

The first formal center for psychedelic research in the world will be launched at Imperial College London today.

Funded with more than £ 3 million from five founding donors, the new Imperial Center for Psychedelic Research will build on over a decade of groundbreaking work in this field conducted at Imperial, including a clinical trial that has launched global efforts for to develop psilocybin treatment for a licensed treatment for depression. It will also examine their potential for treating other conditions, including anorexia.

Led by Dr. Robin Carhart-Harris, the center will focus on two main research topics: the use of psychedelics in mental care; and as a tool to investigate the brain’s consciousness basis.

Psychedelic therapy is very much allowed to treat some very serious mental illnesses and can one day offer new hope to vulnerable people with limited treatment options Dr. Robin Carhart-Harris Head of Center for Psychedelic Research, Imperial College London

The newly established center will be based on Imperial’s Hammersmith campus, which shares space between Imperial College London and the Imperial College Healthcare NHS Trust.

The center also aims to develop a research clinic that can contribute to gathering further clinical evidence and become a prototype for future licensed psychedelic care facilities.

Dr Robin Carhart-Harris, Head of the Imperial Center for Psychedelic Research, said: “This new center represents a watershed for psychedelic science, symbolic of its current general recognition. Psychiatric has a significant impact on neuroscience and psychiatry in the near future. It is a privilege to be at the forefront of one of the most exciting areas of medical science. I am extremely grateful to those donors who have made all of this possible. “

Dr. Carhart-Harris adds:” It may take some years that psychedelic therapy is available to patients, but research so far has been very encouraging Early clinical clinical research has shown that when delivered safely and professionally, psychedelic therapy has a great promise to treat some very serious psychiatric conditions and can offer one day a new one. hope for vulnerable people with limited treatment options. “

Pioneering e research

Over the past decade, a number of research groups in Europe and America have conducted studies on the safety and efficacy of the psychedelic component for conditions such as depression and post-traumatic stress disorder (PTSD), but the new imperial center is the first to get this level of grandeur. within a large academic institution.

Imperial’s psychedelic research group was the first in the world to investigate the brain’s effects of LS D with modern brain imaging and the first to study psilocybin &#821

1; the active compound in magic fungi – for the treatment of severe depression.  Dr Robin Carhart-Harris Dr Robin Carhart-Harris

Other groundbreaking work from the group includes breakthrough neuroimaging research with psilocybin, MDMA and DMT (the psychoactive compounds found in ecstasy and ayahuasca, respectively).

Earlier this year, the group began a new study that directly compared psilocybin treatment with a conventional antidepressant drug in patients with depression – a study for which they are still recruiting volunteers. Because of this, they also plan to launch a new new study next year to investigate the safety and feasibility of psilocybin for the treatment of anorexia patients.

Professor Paul Matthews, Head of Division of Brain Sciences at Imperial, said: “This new Center demonstrates the actual commitment of the UCITS and College to carefully investigate what has hitherto been a fringe of medical science. Internationally leading neuropharmacological research, one day we can better address the widespread and serious mental health conditions that can destroy people’s lives and for which there are currently few effective treatments. “

For more details on the ongoing clinical trial for treatment-resistant depression , contact Ashleigh Murphy: [email protected] and visit the team website for more information.

The trial currently being conducted at Imperial’s Psilocybin for major depression “is a randomized control study in major depressive disorder. The researchers use fMRI to compare the treatment mechanisms for six weeks of daily escitalopram (SSRI antidepressants). ) with two doses of psilocybin The trial began in January 2019 and the team is still recruiting for the participants For complete details, visit the Psychedelic Research Group website

The current trial for psilocybin is performed with the support of the Alexander Mosley Charitable Trust.

Share
Published by
Faela